Millipore Sigma Vibrant Logo

505816 Xanomeline Oxalate - CAS 141064-23-5 - Calbiochem

View This Product on Sigma-Aldrich
505816
価格&在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
141064-23-5C₁₄H₂₃N₃OS•C₂H₂O₄

価格&在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
5.05816.0001
在庫状況検索中…
現在国内在庫なし
現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      ガラスビン 10 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示 
      値引
      ()
       
      弊社照会
      Description
      OverviewAn agonist selective for muscarinic acetylcholine receptor (mAChR) subtype M1 (EC50 = 0.3, 5, 42, 52 and 92.5 nM at M1, M3, M5, M4 and M2 receptors respectively). An antipsychotic agent. Used in improving cognitive deficits and behavioral disturbances in Alzheimer's disease and schizophrenia.
      Catalogue Number505816
      Brand Family Calbiochem®
      Synonyms3-(hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole, Muscarinic Acetylcholine Receptor (mAChR) Agonist, Xanomeline
      References
      ReferencesWang, D., et al., 2011. Biochem. Biophys. Res. Commun. 410, 229.
      Si, W., et al., 2010. Neurosci. Lett. 473, 115.
      Stanhope, et al., 2001. J. Exp. Pharmacol. Ther. 299, 782.
      Product Information
      CAS number141064-23-5
      FormOff-white solid
      Hill FormulaC₁₄H₂₃N₃OS•C₂H₂O₄
      Chemical formulaC₁₄H₂₃N₃OS•C₂H₂O₄
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥99% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C. Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      5.05816.0001 04055977263022

      Documentation

      Xanomeline Oxalate - CAS 141064-23-5 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート((M)SDS) 

      参考資料

      参考資料の概要
      Wang, D., et al., 2011. Biochem. Biophys. Res. Commun. 410, 229.
      Si, W., et al., 2010. Neurosci. Lett. 473, 115.
      Stanhope, et al., 2001. J. Exp. Pharmacol. Ther. 299, 782.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-September-2013 JSW
      Synonyms3-(hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole, Muscarinic Acetylcholine Receptor (mAChR) Agonist, Xanomeline
      DescriptionAn agonist selective for muscarinic acetylcholine receptor (mAChR) subtype M1 (EC50 = 0.3, 5, 42, 52 and 92.5 nM at M1, M3, M5, M4 and M2 receptors respectively). An antipsychotic agent. Used in improving cognitive deficits and behavioral disturbances in Alzheimer′s disease and schizophrenia.
      FormOff-white solid
      CAS number141064-23-5
      Chemical formulaC₁₄H₂₃N₃OS•C₂H₂O₄
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (10 mM) or Ethanol (25 mM)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C. Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesWang, D., et al., 2011. Biochem. Biophys. Res. Commun. 410, 229.
      Si, W., et al., 2010. Neurosci. Lett. 473, 115.
      Stanhope, et al., 2001. J. Exp. Pharmacol. Ther. 299, 782.